New drug cocktail shows promise for Hard-to-Treat lymphoma
NCT ID NCT01955499
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This early-phase trial is testing a combination of two drugs, ibrutinib and lenalidomide, in people with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and understand side effects. About 39 participants with different lymphoma subtypes are being studied to see if the combination can help shrink or slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ibrutinib and lenalidomide
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for patients with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to prior therapy.
What could go wrong
This is an early Phase I trial with only 39 participants, focused on finding the right dose and checking safety. It is too small and early to know if the combination will work better than existing treatments, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.